89 related articles for article (PubMed ID: 35724832)
1. dCas9-mediated dysregulation of gene expression in human induced pluripotent stem cells during primitive streak differentiation.
Haellman V; Pirkl M; Akmammedov A; Saxena P; Beerenwinkel N; Paro R; Teixeira AP; Fussenegger M
Metab Eng; 2022 Sep; 73():70-81. PubMed ID: 35724832
[TBL] [Abstract][Full Text] [Related]
2. Targeted CRISPR activation is functional in engineered human pluripotent stem cells but undergoes silencing after differentiation into cardiomyocytes and endothelium.
Karbassi E; Padgett R; Bertero A; Reinecke H; Klaiman JM; Yang X; Hauschka SD; Murry CE
Cell Mol Life Sci; 2024 Feb; 81(1):95. PubMed ID: 38372898
[TBL] [Abstract][Full Text] [Related]
3. Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells.
Petazzi P; Torres-Ruiz R; Fidanza A; Roca-Ho H; Gutierrez-Agüera F; Castaño J; Rodriguez-Perales S; Díaz de la Guardia R; López-Millán B; Bigas A; Forrester LM; Bueno C; Menéndez P
Mol Ther Nucleic Acids; 2020 Jun; 20():196-204. PubMed ID: 32171171
[TBL] [Abstract][Full Text] [Related]
4. A CRISPRi-dCas9 System for Archaea and Its Use To Examine Gene Function during Nitrogen Fixation by Methanosarcina acetivorans.
Dhamad AE; Lessner DJ
Appl Environ Microbiol; 2020 Oct; 86(21):. PubMed ID: 32826220
[TBL] [Abstract][Full Text] [Related]
5. A review on CRISPR/Cas-based epigenetic regulation in plants.
Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
[TBL] [Abstract][Full Text] [Related]
6. Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.
Li L; Yi H; Liu Z; Long P; Pan T; Huang Y; Li Y; Li Q; Ma Y
Stem Cell Res Ther; 2022 Mar; 13(1):102. PubMed ID: 35255977
[TBL] [Abstract][Full Text] [Related]
7. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery.
De Masi C; Spitalieri P; Murdocca M; Novelli G; Sangiuolo F
Hum Genomics; 2020 Jun; 14(1):25. PubMed ID: 32591003
[TBL] [Abstract][Full Text] [Related]
8. Genome Engineering for Stem Cell Transplantation.
Argani H
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):31-37. PubMed ID: 30777520
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
11. Genome Editing in Human Induced Pluripotent Stem Cells (hiPSCs).
Higo S; Hikoso S; Miyagawa S; Sakata Y
Methods Mol Biol; 2021; 2320():235-245. PubMed ID: 34302662
[TBL] [Abstract][Full Text] [Related]
12. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a second generation homozygous CRISPRa human induced pluripotent stem cell (hiPSC) line for enhanced levels of endogenous gene activation.
Schoger E; Zimmermann WH; Cyganek L; Zelarayán LC
Stem Cell Res; 2021 Oct; 56():102518. PubMed ID: 34481190
[TBL] [Abstract][Full Text] [Related]
14. Inactive Cas9 blocks vitreous-induced expression of Mdm2 and proliferation and survival of retinal pigment epithelial cells.
Chen N; Hu Z; Yang Y; Han H; Lei H
Exp Eye Res; 2019 Sep; 186():107716. PubMed ID: 31278903
[TBL] [Abstract][Full Text] [Related]
15. Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.
Xu X; Tay Y; Sim B; Yoon SI; Huang Y; Ooi J; Utami KH; Ziaei A; Ng B; Radulescu C; Low D; Ng AYJ; Loh M; Venkatesh B; Ginhoux F; Augustine GJ; Pouladi MA
Stem Cell Reports; 2017 Mar; 8(3):619-633. PubMed ID: 28238795
[TBL] [Abstract][Full Text] [Related]
16. Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells.
Kearns NA; Genga RM; Enuameh MS; Garber M; Wolfe SA; Maehr R
Development; 2014 Jan; 141(1):219-23. PubMed ID: 24346702
[TBL] [Abstract][Full Text] [Related]
17. Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation.
Balboa D; Weltner J; Eurola S; Trokovic R; Wartiovaara K; Otonkoski T
Stem Cell Reports; 2015 Sep; 5(3):448-59. PubMed ID: 26352799
[TBL] [Abstract][Full Text] [Related]
18. Targeting the AAVS1 Site by CRISPR/Cas9 with an Inducible Transgene Cassette for the Neuronal Differentiation of Human Pluripotent Stem Cells.
Gu J; Rollo B; Sumer H; Cromer B
Methods Mol Biol; 2022; 2495():99-114. PubMed ID: 35696030
[TBL] [Abstract][Full Text] [Related]
19. Application of CRISPR/Cas9 to the study of brain development and neuropsychiatric disease.
Powell SK; Gregory J; Akbarian S; Brennand KJ
Mol Cell Neurosci; 2017 Jul; 82():157-166. PubMed ID: 28549865
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-Mediated Fluorescent Tagging of Endogenous Proteins in Human Pluripotent Stem Cells.
Sharma A; Toepfer CN; Ward T; Wasson L; Agarwal R; Conner DA; Hu JH; Seidman CE
Curr Protoc Hum Genet; 2018 Jan; 96():21.11.1-21.11.20. PubMed ID: 29364519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
